New ALS therapy in clinical trials

About 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The invariably fatal disease kills the nerve cells that control walking, eating and breathing. Few people survive more than three years after diagnosis. Now, new research led by Washington University School of Medicine in St.

ALS, rare dementia share genetic link

Nearly half of all patients with amyotrophic lateral sclerosis (ALS), a fatal neuromuscular disorder, develop cognitive problems that affect memory and thinking. Why a disease that primarily affects movement also disrupts thinking has been unclear. But now, an international team of researchers has identified genetic links between ALS and frontotemporal dementia, a rare disorder marked

April 10th, 2018|Categories: ALS, Around The State, Disease Specific|Tags: , |

Biomarker Test for Lou Gehrig’s Disease Useful in Diagnosing Canine Neurodegenerative Disease

Mizzou researchers seek clinical trial participants for further treatment study May 03, 2017 Story Contact(s): Jeff Sossamon COLUMBIA, Mo. – In 2009, Joan Coates, a veterinary neurologist, along with other researchers at the University of Missouri and the Broad Institute at MIT/Harvard, found a genetic link between degenerative myelopathy (DM) in dogs and amyotrophic lateral sclerosis

Treatment shows promise in models of fatal neurological disorders

April 25, 2017 At a Glance Researchers found that a gene-silencing drug can reverse or improve symptoms in mouse models of ataxia and amyotrophic lateral sclerosis. The results suggest a new possible therapy for these two untreatable neurological diseases. A drug designed to silence a gene called ataxin 2 improved neuron function in mouse models

A biomarker for tracking the progression of ALS

April 4, 2017  At a Glance Researchers discovered that levels of a protein in urine gradually increased in patients with ALS as their disease progressed over 2 years. These results suggest a potential biomarker to monitor disease progress and the effectiveness of therapies. Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which motor

April 4th, 2017|Categories: ALS|Tags: , , , |

Surprising culprit in nerve cell damage identified

Findings suggest ways to block nerve cell damage in neurodegenerative diseases By Julia Evangelou Strait March 22, 2017 Nerve axons (left) serve as the electrical wiring of the nervous system. Scientists have implicated a specific molecule in triggering a self-destruct program in axons that leads to their degeneration (right). Since axonal degeneration is a common thread

Researcher Finds Evidence Probiotics May Alleviate Progression of ALS

Feb 2, 2017 - KCU staff An imbalance of bacteria in the digestive tract may contribute to the progression of Amyotrophic Lateral Sclerosis (ALS) according to new research led by KCU scientist Jingsong Zhou, PhD and Jun Sun, PhD of University of Illinois at Chicago (UIC). Their preliminary research suggests probiotics could be a potential

February 2nd, 2017|Categories: ALS, Around The State|Tags: , , , |

CIRM-Funded Clinical Trial for ALS Given Go Ahead to Treat Patients

October 24, 2016 Oakland, CA – An ingenious method that uses a patient as their own control has been given clearance to start a clinical trial to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease. The California Institute for Regenerative Medicine (CIRM) is funding the trial. ALS is a devastating disease that

October 24th, 2016|Categories: ALS, Clinical Trials|Tags: , , |